Immunologic approaches to breast cancer treatment

Surgical Oncology Clinics of North America

Volumn 14, Issue 1, 2005, Pages 1-31

  Sabel, Michael S ^a   Nehs, Matthew A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; BETA INTERFERON; CANCER VACCINE; CANVAXIN; CORYNEBACTERIUM PARVUM VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FREUND ADJUVANT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LEVAMISOLE; MELACINE; MELAN A VACCINE; MUCIN 1 VACCINE; PHOSPHORYL LIPID A; POLYADENYLIC POLYURIDYLIC ACID; THERATOPE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOTHERAPY; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CANCER VACCINES; CYTOKINES; FEMALE; GENE TARGETING; HUMANS; IMMUNOTHERAPY;

EID: 8444248863     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2004.07.003     Document Type: Review

References (189)

1. Early Breast Cancer Trialists Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer N Engl J Med 319 1988 1681 1692
2. A.N. Houghton, J.S. Gold, and N.E. Blachere Immunity against cancer: lessons learned from melanoma Curr Opin Oncol 13 2001 134 140
3. H.C. Nauts The beneficial effects of bacterial infections on host resistance to cancer. End results in 449 cases. A study and abstracts of reports in the world medical literature (1775-1980) and personal communications 1980 Cancer Research Institute New York
4. P.I. Haigh, L.A. DiFronzo, G. Gammon, and D.L. Morton Vaccine therapy for patients with melanoma Oncology 13 11 1999 1561 1582
5. D.L. Morton, L.J. Foshag, J.A. Nizze, R.K. Gupta, E. Famatiga, and D.S. Hoon Active specific immunotherapy in malignant melanoma Semin Surg Oncol 5 6 1989 420 425
6. M.L. Disis Immunologic targets for breast cancer Breast Disease 15 2002 83 90
7. K. Chikamatsu, K. Nakano, W.J. Storkus, E. Appella, M.T. Lotze, and T.L. Whiteside Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells Clin Cancer Res 5 1999 1281 1288
8. I.B. Runnebaum, M. Nagarajan, and M. Bowman Mutations in p53 as potential molecular markers for human breast cancer Proc Natl Acad Sci USA 88 1991 10657 10661
9. J.W. Hodge Carcinoembryonic antigen as a target for cancer vaccines Cancer lmmunol Immunother 43 1996 127 134
10. M.J. Scanlan, and D. Jager Challenges to the development of antigen-specific breast cancer vaccines Breast Cancer Res 3 2001 95 98
11. M.A. Watson, and T.P. Fleming Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer Cancer Res 56 1996 860
12. Y.T. Chen, A.O. Gure, S. Tsang, E. Stockert, E. Jager, and A. Knuth Identification of multiple cancer/testis (CT) antigens by allogeneic antibody screening of a melanoma cell line library Proc Natl Acad Sci USA 95 1998 6919 6923
13. U. Sahin, O. Tureci, Y.T. Chen, G. Seitz, C. Villena-Heinsen, and L.J. Old Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies Int J Cancer 78 1998 387 389
14. R. Nahta, G.N. Hortobagyi, and F.J. Esteva Growth factor receptors in breast cancer: potential for therapeutic intervention Oncologist 8 2003 5 17
15. C.I. Spiridon, M. Ghetie, J. Uhr, R. Marches, J. Li, G. Shen, and E.S. Vitetta Targeting multiple HER-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo Clin Cancer Res 8 2002 1720 1730
16. S. von Mensdorff-Pouilly, A.A. Verstraeten, P. Kenemans, F.G. Snijdewint, A. Kok, and G.J. Van Kamp Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin J Clin Oncol 18 2000 574 583
17. B. Agrawal, M.J. Krantz, M.A. Reddish, and B.M. Longenecker Does pregnancy immunize against breast cancer? Cancer Res 55 1995 2257 2261
18. G.Q. Phan, P. Attia, S.M. Steinberg, D.E. White, and S.A. Rosenberg Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma J Clin Oncol 19 2001 3477 3482
19. C. Yee, J.A. Thompson, P. Roche, D.R. Byrd, P.P. Lee, M. Peipkorn, and K. Kenyon Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell mediated vitiligo J Exp Med 192 11 2000 1637 1644
20. I. Penn Malignant melanoma in organ allograft recipients Transplantation 61 1996 274 278
21. S. Euvrard, J. Kanitakis, and A. Claudy Skin cancers after organ transplantation N Engl J Med 348 2003 1681 1691
22. T. Stewart, J. Tsai, H. Grayson, R. Henderson, and G. Opelz Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation Lancet 346 1995 796 798
23. S. Menard, G. Tomasic, P. Casalini, A. Balsari, S. Pilotti, and N. Cascinelli Lymphoid infiltration as a prognostic variable for early onset breast carcinomas Clin Cancer Res 3 1997 817 819
24. P.P. Rosen, S. Groshen, P.E. Saigo, D.W. Kinne, and S. Hellman Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years J Clin Oncol 7 1989 1239 1251
25. M.L. Disis, and M.A. Cheever HER-2/neu protein. A target for antigen specific immunotherapy of human cancer Adv Cancer Res 71 1997 343 371
26. M.L. Disis, E. Calenoff, G. McLaughlin, A.E. Murphy, W. Chen, and B. Groner Existent T-cell and antibody immunity to HER2/neu protein in patients with breast cancer Cancer Res 54 1994 16 20
27. S.M. Pupa, S. Menard, S. Adreola, and M.I. Colnaghi Antibody response against the c-erb-2 oncoprotein in breast carcinoma patients Cancer Res 53 1993 5864 5866
28. M.L. Disis, S.M. Pupa, J.R. Gralow, R. Dittadi, S. Menard, and M.A. Cheever High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer J Clin Oncol 15 1997 3363 3367
29. S.M. Barralt-Boyes Making the most of mucin: a novel target for tumor immunotherapy Cancer Immunol Immunother 43 1996 142 151
30. T.H.M. Stewart The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their own tumors Cancer 23 1969 1368 1387
31. L.J. Old, D.A. Clarke, and B. Benacerraf Effect of bacillus Calmette-Guerin infection on transplanted tumors in the mouse Nature 184 1959 291
32. J. Gutterman, G.R. Blumenschein, and G.N. Hortobagyi Immunotherapy for breast cancer Breast 2 1976 29
33. A.U. Buzdar, G.R. Blumenschein, and T.L. Smith Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED) J Surg Oncol 12 1979 27 40
34. L. Nathanson Immunology and immunotherapy of human breast cancer Cancer Immunol Immunother 2 1977 209
35. B. Fisher, A. Brown, N. Wolmark, E.R. Fisher, C. Redmond, and D.L. Wickerham Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary cancer Cancer 66 1990 220 227
36. S. Retsas, R.H. Phillips, I.W. Hanham, and K.A. Newton Agranulocytosis in breast cancer patients treated with levamisole Lancet 2 1978 324 325
37. A.F. Rojas, J.N. Feierstein, E. Mickiewicz, H. Glait, and A.J. Olivari Levamisole in advanced human breast cancer Lancet 1 1976 211 215
38. H.M. Anthony Adjuvant levamisole in breast cancer Lancet 2 1980 1123 1124
39. Y. Hirshaut, H. Kesselheim, C.M. Pinsky, D. Braun Jr., H.J. Wanebo, and H.F. Oettgen Levamisole as an immunoadjuvant: phase I study and application in breast cancer Cancer Treat Res 62 1978 1693 1701
40. F. Lacour, J. Lacour, A. Spira, M. Michelson, G. Delage, and J.Y. Petit A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer Recent Results Cancer Res 80 1982 200 206
41. V. Barak, I. Kalickman, B. Nisman, H. Farbstein, Z.G. Fridlender, and L. Baider Changes in cytokine production of breast cancer patients treated with interferons Cytokine 10 1998 977 983
42. S. Grabbe, S. Bruvers, S. Beissert, and R.D. Granstein Interferon-gamma inhibits tumor antigen presentation by epidermal antigen-presenting cells J Leukoc Biol 55 1994 695 701
43. Y. Rongcun, H. Maes, M. Corsi, F. Dellner, T. Wen, and R. Kiessling Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumor-specific and allo-specific antigens and reduces their expression of CD1A, CD80 and CD4 Cytokine 10 1998 747 755
44. J.U. Gutterman, G.R. Blumenschein, R. Alexanian, H.Y. Yap, A.U. Buzdar, and F. Cabanillas Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma Ann Intern Med 93 1980 399 406
45. E.C. Borden, and F.R. Balkwill Preclinical and clinical studies of interferons and interferon inducers in breast cancer Cancer 53 1984 783 789
46. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher First-line herceptin monotherapy in metastatic breast cancer Oncology 61 Suppl S2 2001 37 42
47. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
48. M. Katsumata, T. Okudaira, A. Samanta, D.P. Clark, J.A. Drebin, P. Jolicoeur, and M.I. Greene Prevention of breast tumour development in vivo by downregulation of the p185neu receptor Nat Med 1 1995 644 648
49. C.M. Buschenfelde, C. Hermann, B. Schmidt, and C. Peschel Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells Cancer Res 62 2002 2244 2247
50. S. Cooley, L.J. Burns, T. Repka, and J.S. Miller Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody dependent cellular cytotoxicity against LFA-3 and HER2/neu Exp Hematol 27 1999 1533 1541
51. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
52. T. Repka, E.G. Chiorean, J. Gay, K.E. Herwig, V.K. Kohl, and D. Yee Trastuzumab and interleukin-2 in HER-2 positive metastatic breast cancer: A pilot study Clin Cancer Res 9 2003 2440 2446
53. Parihar R, Nadella P, Jensen R, et al. A phase I trial of interleukin-12 and herceptin reveals a correlation between increased cytokine production by natural killer cells and clinical response. Presented at the Genetech Solid Tumor Investigator's Meeting, 2002.
54. S.E. Wright, K.A. Rewers-Felkins, I.S. Quinlin, P.W. Eldridge, P.E. Zorsky, and P.P. Klug Adoptive immunotherapy of mucin 1 expressing adenocarcinomas with mucin 1 stimulated human peripheral blood mononuclear cells Int J Mol Med 9 2002 401 404
55. C. Akewanlop, M. Watanabe, B. Singh, M. Walker, D.W. Kufe, and D.F. Hayes Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody DF3 and its bispecific antibody Cancer Res 61 2001 4061 4065
56. S. Braun, F. Hepp, C.R. Kentenich, W. Janni, K. Pantel, and G. Reithmuller Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow Clin Cancer Res 5 12 1999 3999 4004
57. E.M. Kirchner, R. Gerhards, and R. Voigtmann Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A positive disseminated tumour cells Ann Oncol 13 7 2002 1044 1048
58. R.H. Yonemoto, and P.I. Terasaki Cancer immunotherapy with HLA-compatible thoracic duct lymphocyte transplantation. A preliminary report Cancer 30 1972 1438 1443
59. G.E. Moore, and R.E. Gerner Cancer immunity - hypothesis and clinical trial of lymphocyto-therapy for malignant diseases Ann Surg 174 1970 733 739
60. H. Soda, K. Koda, J. Yasutomi, K. Oda, N. Takiguchi, and N. Saito Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic lymphocytes J Surg Oncol 72 1999 211 217
61. V. Schirrmacher, M. Feuerer, P. Beckhove, T. Ahlert, and V. Umansky T cell memory, anergy and immunotherapy in breast cancer J Mammary Gland Biol Neoplasia 7 2002 201 208
62. L.G. Lum, A.V. LeFever, J.S. Treisman, N.K. Garlie, and J.P. Hanson Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells - phase I clinical trial J Immunother 24 2001 408 419
63. +T cells, infusional interleukin-2 and cyclophosphamide in patients with advanced cancer J Clin Oncol 16 1998 2752 2760
64. H. Soda, K. Koda, J. Yasutomi, K. Oda, N. Takiguchi, N. Saito, and N. Nakajima Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic lymphocytes J Surg Oncol 72 1999 211 217
65. A. Terando, and A.E. Chang Applications of gene transfer to cellular immunotherapy Surg Oncol Clin N Am 11 2002 621 643
66. R. Kass, S. Bellone, M. Palmieri, S. Cane, E. Bignotti, and R. Henry-Tilman Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells Breast Cancer Res Treat 80 2003 275 285
67. C.N. Baxevanis, G.V. Dedoussis, and N.G. Papadopoulos Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer Cancer 74 1994 1275 1282
68. D.J. Schwartzentruber, D. Solomon, S.A. Rosenberg, and S.L. Topalian Characteristics of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion J Immunother 12 1992 1 12
69. M.E. Dudley, and S.A. Rosenberg Adoptive-cell-transfer therapy for the treatment of patients with cancer Nature Reviews 3 2003 666 676
70. S.L. Topalian, D. Solomon, F.P. Avis, A.E. Chang, D.L. Freerksen, and W.M. Linehan Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study J Clin Oncol 6 1988 839 853
71. S.K. Hoover, J.L. Frank, C. McCrady, J.G. McKinnon, and H.D. Bear Activation and in vitro expansion of tumor reactive T lymphocytes from lymph nodes draining human primary breast cancers J Surg Oncol 46 1991 117 124
72. T. Okino, N. Kan, M. Nakanishi, K. Satoh, K. Mise, and Y. Teramura The therapeutic effect of OK-432 combined adoptive immunotherapy against liver metastases from breast cancer J Cancer Res Clin Oncol 116 1990 197 202
73. A.E. Chang, H. Yoshizawa, K. Sakai, M.J. Cameron, V.K. Sondak, and S. Shu Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro Cancer Res 53 1993 1043 1050
74. A.E. Chang, A. Aruga, M.J. Cameron, V.K. Sondak, D.P. Normolle, B.A. Fox, and S. Shu Adoptive immunotherapy with vaccine primed lymph node cells secondarily activated with anti-CD3 and interleukin-2 J Clin Oncol 15 1997 796 807
75. + effector cells in a murine mammary model J Immunother 23 2000 225 234
76. E. Aruga, A. Aruga, M.J. Arca, W.M.F. Lee, N.-S. Yang, and J.W. Smith Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF Cancer Gene Ther 4 1997 157 166
77. K.L. Knutson, P. Crosby, and M.L. Disis Isolation of HER-2/neu specific T cell clones from a breast cancer patient following immunization with a HER2 peptide vaccine Proc Am Assoc Cancer Res 40 1999 310
78. M. Reddish, G.D. MacLean, R.R. Kogarty, J. Kan-Mitchell, V. Jones, and M.S. Mitchell Anti-MUCI class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUCI peptide Int J Cancer 76 1998 817 823
79. C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, and H.G. Klingemann Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood 100 2002 1265 1273
80. M. DeMagalhaes-Silverman, A. Donnenberg, B. Lembersky, E. Elder, J. Lister, and W. Rybka Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer J Immunother 23 2000 154 160
81. J.A. Sparano, R.I. Fisher, G.R. Weiss, K. Margolin, F.R. Aranson, and M.J. Hawkins Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, pancreas and other tumors J Immunother Emphasis Tumor Immunol 16 1994 216 232
82. S. Visonneau, A. Cesano, M.H. Torosian, and D. Santoli Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice Clin Cancer Res 3 1997 1491 1500
83. S. Visonneau, A. Cesano, D.L. Porter, S.L. Luger, L. Schuchter, and M. Kamoun Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer Clin Cancer Res 6 2000 1744 1754
84. D.A. Cameron Breast cancer vaccines: current research and future prospects Expert Rev Vaccines 1 2002 29 34
85. J.S. Goydos, E. Elder, T.L. Whiteside, O.J. Finn, and M.T. Lotze A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma J Surg Res 63 1996 298 304
86. K.L. Knutson, K. Schiffman, K. Rinn, and M.L. Disis Immunotherapeutic approaches for the treatment of breast cancer J Mammary Gland Biol Neoplasia 4 1999 353 365
87. V. Karanikas, A. Hwang, J. Pearson, C.S. Ong, V. Apostolopoulos, and H. Vaughan Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUCI fusion protein J Clin Invest 100 1997 2783 2792
88. I. Correa, and T. Plunket Update on HER-2 as a target for cancer therapy HER2/neu peptides as tumour vaccines for T cell recognition Breast Cancer Res 3 2003 399 403
89. M.L. Disis, K. Schiffman, T.A. Gooley, D.G. McNeel, K. Rinn, and K.L. Knutson Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization Clin Cancer Res 6 2000 1347 1350
90. M.L. Disis, T.A. Gooley, K. Rinn, D. Davis, M. Piepkorn, and M.A. Cheever Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J Clin Oncol 20 11 2002 2624 2632
91. P. Brossart, S. Wirths, G. Stuhler, V.L. Reichardt, L. Kanz, and W. Brugger Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells Blood 96 2000 3102 3108
92. M.L. Disis, K.H. Grabstein, P.R. Sleath, and M.A. Cheever Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine Clin Cancer Res 5 1999 1289 1297
93. J.L. Murray, D. Przepiorka, and C.G. Ioannides Clinical trials of HER-2/neu-specific vaccines Semin Oncol 27 6 Suppl 11 2000 71 75
94. + tumors Cancer Res 58 1998 4902 4908
95. N.K. Dakappagari, D.B. Douglas, P.L. Triozzi, V.C. Stevens, and P.T. Kaumaya Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine Cancer Res 60 2000 3782 3789
96. Y.L. Yip, G. Smith, J. Koch, S. Dubel, and R.L. Ward Identification of epitope regions recognized by tumor inhibitory and stimulatory antiErbB-2 monoclonal antibodies: implications for vaccine design J Immunol 166 2001 5271 5278
97. + patients with metastatic breast and ovarian cancer Clin Cancer Res 8 2002 3407 3418
98. K.L. Knutson, K. Schiffman, M.A. Cheever, and M.L. Disis Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide specific immunity Clin Cancer Res 8 2002 1014 1018
99. T.M. Foy, G.R. Fanger, S. Hand, C. Gerard, C. Bruck, and M.A. Cheever Designing HER2 vaccines Semin Oncol 29 3 Suppl 11 2002 53 61
100. Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol (6 Suppl 18):12-20.
101. J. Jasinska, S. Wagner, C. Radauer, R. Sedivy, T. Brodowicz, and C. Wilschke Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of HER2/neu Int J Cancer 107 2003 976 983
102. M.V. Croce, and A. Segal-Eiras The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer Drugs Today (Barc) 38 2002 759 768
103. A. Carr, E. Rodriguez, M. del Carmen Arango, R. Camacho, and M. Osorio Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine J Clin Oncol 21 2003 1015 1021
104. M.A. Morse Technology evaluation: Theratope, Biomira, Inc Curr Opin Mol Ther 2 2000 453 458
105. L.A. Holmberg, and B.M. Sandmaier Theratope vaccine (STn-KLH) Exp Opin Biol Ther 1 2001 881 891
106. B.M. Longenecker, M. Reddish, R. Koganty, and G.D. MacLean Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant Ann N Y Acad Sci 690 1993 276 291
107. J. Lindenmann Speculations on idiotypes of homobodies Ann Immunol (Paris) 124 1973 171 184
108. N.K. Jerne Towards a network theory of the immune system Ann Immunol (Paris) 125C 1974 373 389
109. M.B. Chatterjee, K.A. Foon, and H. Kohler Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine Cancer Immunol Immunother 49 2000 133 141
110. M. Bhattacharya-Chatterjee, and G. Kohler Anti-idiotype tumor vaccines Adv Exp Med Biol 251 1990 113 128
111. M.B. Chatterjee, K.A. Foon, and H. Kohler Idiotypic antibody immunotherapy of cancer Cancer Immunol Immunother 38 1994 75 82
112. A. Mittelman, X. Wang, K. Matsumoto, and S. Ferrone Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23 Hybridoma 14 1995 175 181
113. M. Bhattacharya-Chatterjee, S.K. Chatterjee, and K.A. Foon Anti-idiotype vaccine against cancer Immunol Lett 74 2000 51 58
114. R.K. Munn, L. Hutchins, J. Garrison, G. Sen, M. Chakraborty, and R. Baral Immune responses in patients with breast cancer treated with an anti-idiotypic antibody that mimics the human milk fat globule (HMFG) antigen Proc Am Soc Clin Oncol 17 1998 428
115. A. Diaz, M. Alfonso, R. Alonso, G. Saurez, M. Troche, and M. Catala Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides Clin Immunol 107 2003 80 89
116. R.O. Dillman, L.D. Beutel, C. De Leon, and S.K. Nayak Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer Cancer Biother Radiopharm 16 2001 205 211
117. W. Wood, and R.D. Baynes Vaccination of stage IV breast cancer patients with whole autologous malignant cells and granulocyte macrophage colony stimulating factor Proc Am Soc Clin Oncol 18 1999 437a
118. T. Ahlert, W. Sauerbrei, G. Bastert, S. Ruhland, B. Bartik, and N. Simiantonaki Tumor cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer J Clin Oncol 15 1997 1354 1366
119. D.L. Morton, L.J. Foshag, D.S. Hoon, J.A. Nizze, E. Famatiga, L.A. Wanek, C. Chang, D.G. Davtyan, R.K. Gupta, and R. Elashoff Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463 482
120. V.K. Sondak, P.Y. Liu, R.J. Tuthill, R.A. Kempf, J.M. Unger, and J.A. Sosman Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group J Clin Oncol 20 8 2002 2058 2066
121. S.E. Townsend, F.W. Su, J.M. Atherton, and J.P. Allison Specificity and longevity of antitumor immune responses induced by B7-transfected tumors Cancer Res 54 1994 6477 6483
122. S.J. Antonia B7-1 gene-modified tumor cell vaccines Curr Opin Mol Ther 1 1999 50 56
123. A. Dols, J.W. Smith, S.L. Meijer, B.A. Fox, H.-M. Hu, and E. Walker Vaccination of women with metastatic breast cancer using a costimulatory gene (CD80)-modified, HLA-A2-matched allogeneic breast cancer cell line: clinical and immunological results Hum Gene Ther 14 2003 1117 1123
124. D.D. Schoof, J.W. Smith, M.L. Disis, P. Brant-Zawadski, W. Wood, and T. Doran Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF Adv Exp Med Biol 451 1998 511 518
125. A. Dols, S. Meijer, H.-M. Hu, V. Goodell, M.L. Disis, and S. von Mensdorff-Pouilly Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells J Immunother 26 2003 163 170
126. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
127. F.O. Nestle, J. Banchereau, and D. Hart Dendritic cells: on the move from bench to bedside Nat Med 7 7 2001 761 765
128. J.J. Hernando, T.W. Park, and W.C. Kuhn Dendritic cell-based vaccines in breast and gynaecologic cancer Anticancer Res 23 2003 4293 4303
129. P. Brossart, S. Wirths, W. Brugger, and L. Kanz Dendritic cells in cancer vaccines Exp Hematol 29 2001 1247 1255
130. T.A. Plunkett, I. Correa, D.W. Miles, and J. Taylor-Papadimitriou Breast cancer and the immune system: Opportunities and pitfalls J Mammary Gland Biol Neoplasia 6 2001 467 475
131. P. Brossart, S. Wirths, G. Stuhler, V.L. Reichardt, L. Kanz, and W. Brugger Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells Blood 96 2000 3102
132. M.A. Morse, Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, and S. Nair A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen Clin Cancer Res 5 1999 1331 1338
133. + cytotoxic T lymphocytes against breast cancer cells by stimulation with mammaglobin-A pulsed dendritic cells Breast Cancer Res Treat 79 2003 133 136
134. Z. Si, P. Hersey, and A.S. Coates Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF Melanoma Res 6 1996 247 255
135. A.H. Rook, G.S. Wood, E.K. Yoo, R. Elenitsas, D.M. Kao, and M.L. Sherman Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses Blood 94 1999 902 908
136. D.V. Habif, L. Ozzello, C.M. De Rosa, K. Cantell, and R. Lattes Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma Cancer Invest 13 1995 165 172
137. B. Gansbacher, K. Zeier, B. Daniels, K.C. Cronin, R. Bennerji, and E. Gilboa Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity J Exp Med 172 1990 1217 1224
138. E.R. Fearon, D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, and J.W. Simons Interleukin-2 production by tumor cells bypass T helper function in the generation of an antitumor response Cell 60 1990 397 403
139. R.I. Tepper, P.K. Pattengal, and P. Leder Murine interleukin-4 displays potent anti-tumor activity in vivo Cell 57 1989 503 512
140. M.T. Lotze, and J.T. Rubin Gene therapy of cancer: a pilot study of IL-4 gene modified fibroblasts admixed with autologous tumor to elicit an immune response Hum Gene Ther 5 1994 41 55
141. H. Tahara, H.J. Zeh 3rd, W.J. Storkus, I. Pappo, S.C. Watkins, and U. Gubler Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity of a murine melanoma in vivo Cancer Res 54 1994 182 189
142. M.J. Brunda, L. Luistro, R.R. Warrier, R.B. Wright, B.R. Hubbard, and M. Murphy Antitumor and antimetastatic activity of interleukin-12 against murine tumors J Exp Med 178 1993 1223 1230
143. L. Zitvogel, H. Tahara, P.D. Robbins, W.J. Storkus, M.R. Clarke, and M.A. Nalesnik Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts J Immunol 155 1995 1393 1403
144. H. Tahara, L. Zitvogel, and W.J. Storkus Antitumor effects in patients with melanoma, head and neck and breast cancer in a Phase I/II clinical trial of interleukin-12 (IL-12) Proc Am Soc Clin Oncol 16 1997 439a
145. M.L. Albert, B. Sauter, and N. Bhardwaj Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature 392 1998 86 89
146. M.T. Lotze Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer Ann Surg 226 1997 1 5
147. M. Iwamoto, H. Shinohara, A. Miyamoto, M. Okuzawa, H. Mabuchi, and T. Nohara Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas Int J Cancer 104 2003 92 97
148. K.A. Candido, K. Shimuzu, J.C. McLaughlin, R. Kunkel, J.A. Fuller, and B.G. Redman Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents Cancer Res 61 2001 228 236
149. D.A. Sewell, and J.T. Santoso Adenovirus-based p53 gene therapy in ovarian cancer Gyn Oncol 59 1995 171 178
150. H. Gahery-Segard Phase I trial of recombinant adenovirus gene therapy in lung cancer. Longitudinal study of the immune responses to transgene and viral products J Clin Invest 100 1997 2218 2226
151. E.M. Toloza In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector Cancer Gene Ther 3 1996 11 17
152. A. Porgador Anti-metastatic vaccination of tumor-bearing mice with IL-2 gene inserted tumor cells Int J Cancer 53 1993 471 477
153. K.S. Zier, S. Salvadori, K.C. Cronin, and B. Gansbacher Vaccination with IL-2 secreting tumor cells stimulates the generation of IL-2 responsive T-cells and prevents the development of unresponsiveness Cancer Gene Ther 1 1994 43 50
154. Y. Nasu, C.H. Bangma, G.W. Hull, H.M. Lee, J. Hu, and J. Wang Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model Gene Ther 6 1999 338 349
155. A. Gambotto, T. Tuting, D.L. McVey, I. Kovesdi, H. Tahara, and M.T. Lotze Induction of antitumor immunity by direct intratumoral injection of recombinant adenovirus vector expressing interleukin-12 Cancer Gene Ther 6 1999 45 53
156. G. Mazzolini, C. Qian, X. Xie, Y. Sun, J.J. Lasarte, and M. Drozdzik Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12 Cancer Gene Ther 6 1999 514 522
157. M.J. Mastrangelo, H.C. Maguire Jr., L.C. Eisenlohr, C.E. Laughlin, C.E. Monken, and P.A. McCue Intratumoral recombinant GM-CSF encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther 6 1998 409 422
158. P.C.R. Emtage, Y. Wan, J.L. Bramson, F.L. Graham, and J. Gauldie A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human I1-2 induces complete tumor regression in a murine breast adenocarcinoma model J Immunol 160 1998 2531 2538
159. C.L. Addison Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model Proc Natl Acad Sci USA 92 1995 8522 8526
160. C.L. Addison Intratumoral co-injection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors Gene Ther 5 1998 1400 1409
161. H. Haddada Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces anti-tumoral immunity in mice Hum Gene Ther 6 1993 703 711
162. A.K. Stewart, N.J. Lassam, I.C. Quirt, D.J. Bailey, L.E. Rotstein, and M. Krajden Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase I clinical trial Gene Ther 6 1999 350 363
163. M.P. Colombo, and G. Forni Immunotherapy I: cytokine gene transfer strategies Cancer Metastases Rev 16 1997 421 432
164. G. Dranoff Cancer gene therapy: connecting basic research with clinical inquiry J Clin Oncol 16 1998 2548 2556
165. R. Langer Drug delivery and targeting Nature 392 1998 5 10
166. P. Menei Local and sustained delivery of 5-flourouracil from biodegradable microspheres for the radiosensitization of glioblastoma Cancer 86 1999 325 330
167. D.T. O'Hagan, M. Singh, and R.K. Gupta Poly lactide-co-glycolide microparticles for the development of single-dose controlled-release vaccines Adv Drug Del Rev 32 1998 225 246
168. S.D. Putney, and P.A. Burke Improving protein therapeutics with sustained-releases formulations Nat Biotechnol 16 1998 153 157
169. P.T. Golumbek, R. Azhari, E.M. Jaffee, H.I. Levitsky, A. Lazenby, K. Leong, and D.M. Pardoll Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design Cancer Res 53 1993 5841 5844
170. L. Chen, R.N. Apre, and S. Cohen Characterization of PLGA microspheres for the controlled delivery of IL-la for tumor immunotherapy J Control Release 43 1998 261 272
171. N.K. Egilmez, Y.S. Jong, Y. Iwanuma, J.S. Jacob, C.A. Santos, and F.A. Chen Cytokine immunotherapy of cancer with controlled release biodegradable
172. N.K. Egilmez, Y.S. Jong, M.S. Sabel, J.S. Jacob, E. Mathiowitz, and R.B. Bankert In situ tumor vaccination with interleukin-12 encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity Cancer Res 60 2000 3832 3837
173. M.S. Sabel, H. Hill, Y.S. Jong, E. Mathiowitz, R.B. Bankert, and N.K. Egilmez Neoadjuvant therapy with interleukin-12 loaded polylactic acid microspheres reduces local recurrence and distant metastases Surgery 130 2001 470 478
174. H.C. Hill, T.F. Conway Jr., M.S. Sabel, Y.S. Jong, E. Mathiowitz, and R.B. Bankert Tumor vaccination with IL-12 and GM-CSF encapsulated microspheres: co-induction of innate and adaptive anti-tumor immunity and cure of disseminated disease Cancer Res 62 2003 7254 7263
175. M.S. Sabel, J. Skitzki, L. Stoolman, N.K. Egilmez, E. Mathiowitz, and N. Bailey Intratumoral IL-12 and TNF-alpha loaded microspheres lead to regression of breast cancer and systemic antitumor immunity Ann Surg Oncol 11 2 2004 147 156
176. B. Seliger, M. Maeurer, and S. Ferrone Antigen-processing machinery breakdown and tumor growth Immunol Today 21 2000 455 464
177. A. Maiorana, A.M. Cesinaro, R.A. Fano, and G. Collina Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases Clin Exp Metastasis 13 1995 43 48
178. Early Breast Cancer Trialists Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy Lancet 339 1992 1 15
179. T.H.M. Stewart, M.W. Retsky, S.C.J. Tsai, and S. Verma Dose response in the treatment of breast cancer Lancet 343 1994 402 404
180. P.B. Seghal, and I. Tamm Interleukin-6 enhances motility of breast carcinoma cells I.D. Goldberg Cell motility factors 1991 Birkhauser Verlag Basel (Switzerland) 178 193
181. A. Freund, C. Chauveau, J.P. Brouillet, A. Lucas, M. Lacroix, and A. Licznar IL-8 expression and its possible relationship with estrogen-receptor negative status of breast cancer cells Oncogene 22 2003 256 265
182. A.R. Green, V.L. Green, M.C. White, and V. Speirs Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: Identification of interleukin-8 as a potential regulatory factor in breast tumors Int J Cancer 72 1997 937 941
183. E. Venetsanakos, I. Beckman, J. Bradley, and J. Skinner High incidence of interleukin-10 mRNA but not interleukin-2 mRNA detected in human breast tumors Br J Cancer 75 1997 1826 1830
184. S.M. Scholl, P. Crocker, R. Tang, P. Pouillart, and J.W. Pollard Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol Carcinog 7 1993 207 211
185. G.E. Peoples, S. Blotnik, K. Takahashi, M.R. Freeman, M. Klagsbrun, and T.J. Eberlen T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor like growth factor and basic fibroblast growth factor: a potential pathologic role Proc Natl Acad Sci USA 92 1995 6547 6551
186. Q. Lu, and A. Brodie Stimulation of the growth of MCF-7 and MDA-MB-468 breast cancer cells by vascular endothelial growth factor Proc Am Assoc Cancer Res 37 1996 220
187. S.C.J. Tsai, F. Miller, W.Z. Wei, and G.H. Heppner Tumor necrosis factor (TNF) modulates growth of normal and neoplastic murine mammary cells Proc Am Assoc Cancer Res 33 1992 269
188. E.M. Rosen, I.D. Goldberg, D. Liu, E. Setter, M.A. Donovan, and M. Bhargava Tumor necrosis factor stimulates epithelial tumor cell motility Cancer Res 51 1991 5315 5321
189. S.C.J. Tsai, and G.H. Heppner Immunoendocrine mechanisms in mammary tumor progression direct prolactin modulation of peripheral and preneoplastic hyperplastic-alveolar-nodule infiltrating lymphocytes Cancer Immunol Immunother 39 1994 291 298